Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neostigmine methylsulfate + glycopyrronium bromide
- Development stage
- Unknown
- Lead developer
- Pirkanmaan hyvinvointialue
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Glycostigmin is a fixed-dose combination of neostigmine methylsulfate and glycopyrronium bromide, developed by Pirkanmaan hyvinvointialue (Tampere University Hospital) for use in anesthesia. Neostigmine is an acetylcholinesterase inhibitor that reverses the effects of non-depolarizing neuromuscular blocking agents by increasing the concentration of acetylcholine at the neuromuscular junction. Glycopyrronium bromide is a muscarinic antagonist included to prevent the cholinergic side effects of neostigmine, such as bradycardia and hypersalivation, by blocking muscarinic receptors in the heart and exocrine glands. This combination is typically administered intravenously at the end of surgery to restore muscle function while maintaining hemodynamic stability.
- Brand names
- Glycostigmin
- Other names
- neostigmine/glycopyrronium combination
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM5 (M5)CHRM3 (M3)Acetylcholinesterase
Beyond the preview
Go deeper on neostigmine methylsulfate + glycopyrronium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neostigmine methylsulfate + glycopyrronium bromide.